New Aspects of Ultrasound-Mediated Targeted Delivery and Therapy for Cancer
Open Access
- 1 January 2020
- journal article
- review article
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 15, 401-418
Abstract
Ultrasound-mediated targeted delivery (UMTD), a novel delivery modality of therapeutic materials based on ultrasound, shows great potential in biomedical applications. By coupling ultrasound contrast agents with therapeutic materials, UMTD combines the advantages of ultrasound imaging and carrier, which benefit deep tissue penetration and high concentration aggregation. In this paper we introduced recent advances in ultrasound contrast agents and applications in tumor therapy. Ultrasound contrast agents were categorized by their functions, mainly including thermosensitive, pH-sensitive and photosensitive ultrasound contrast agents. The various applications of UMTD in tumor treatment were summarized as follows: drug therapy, transfection of anti-oncogene, RNA interference, vaccine immunotherapy, monoclonal antibody immunotherapy, adoptive cellular immunotherapy, cytokine immunotherapy, and so on. In the end, we elaborated on the current challenges and provided perspectives of UMTD for clinical applications.Keywords
This publication has 150 references indexed in Scilit:
- Hypoxia–Induced Cytotoxic Drug Resistance in Osteosarcoma Is Independent of HIF-1AlphaPLOS ONE, 2013
- Adjuvant trastuzumab in elderly with HER-2 positive breast cancer: A systematic review of randomized controlled trialsCancer Treatment Reviews, 2013
- Hyperbaric oxygen therapy and cancer—a reviewTargeted Oncology, 2012
- DNA fusion-gene vaccination in patients with prostate cancer induces high-frequency CD8+ T-cell responses and increases PSA doubling timeCancer Immunology, Immunotherapy, 2012
- Multi-modal strategies for overcoming tumor drug resistance: Hypoxia, the Warburg effect, stem cells, and multifunctional nanotechnologyJournal of Controlled Release, 2011
- Progress and prospects: immune responses to viral vectorsGene Therapy, 2009
- MicroRNA-122 Inhibits Tumorigenic Properties of Hepatocellular Carcinoma Cells and Sensitizes These Cells to SorafenibJournal of Biological Chemistry, 2009
- miRNA control of tumor cell invasion and metastasisInternational Journal of Cancer, 2009
- Tumor microvasculature and microenvironment: Targets for anti-angiogenesis and normalizationMicrovascular Research, 2007
- Expression and Targeting of the Apoptosis Inhibitor, Survivin, in Human MelanomaJournal of Investigative Dermatology, 1999